Profound Med Corp SEC Filings

Profound Medical Corp. reported the results of its 2026 annual and special shareholder meeting. Shareholders elected eight directors, including two new nominees, to serve until the next annual meeting. Support for individual directors ranged from about 79% to 91% of votes cast.

Shareholders approved the appointment of PricewaterhouseCoopers LLP as auditors, with 25,193,910 votes for and 99.497% support. They also approved an ordinary resolution confirming all unallocated restricted share units and deferred share units under the long-term incentive plan, with 9,046,376 votes for and 63.922% support versus 36.078% against. The circular notes 36,337,637 common shares outstanding as of April 2, 2026, and describes the company’s equity-based compensation, governance structure, and executive/director pay philosophy.

Profound Medical Corp. furnished a current report describing plans to spotlight its MRI-guided TULSA Procedure™ at the American Urological Association’s 2026 Annual Meeting in Washington, DC. Four oral presentations on MRI-guided transurethral ultrasound ablation for localized prostate cancer will be delivered by clinicians from Mayo Clinic, Turku University Hospital and Sapporo Hokuyu Hospital.

The company will also demonstrate TULSA-PRO® and a Siemens Free.Max MR system at Booth #413 and has launched an initiative to explore integrating PSMA PET molecular imaging with TULSA-PRO treatment planning. This effort aims to support intent-to-treat decisions and patient monitoring across focal, subtotal and whole-gland prostate ablation strategies.

Profound Medical Corp. registers for resale up to 921,428 common shares previously issued in a private placement closed on December 30, 2025. The shares were issued at $7.00 per share for aggregate gross proceeds of $6.45 million. The company will not receive proceeds from resales.

The prospectus states the selling shareholders may sell shares at fixed or market prices, through underwriters, broker-dealers or agents, and by other customary methods. The registration permits resale on Nasdaq ("PROF") and the Toronto Stock Exchange ("PRN").

Profound Medical Corp. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose to $5,337 from $2,621 a year earlier, driven by higher capital equipment sales and recurring device revenue, while gross margin held near 72%.

Operating expenses fell to $11,853 from $13,019, narrowing the net loss to $7,053 from $10,724, or $0.19 per share versus $0.36. Cash declined to $50,295 from $59,723 at December 31, 2025, mainly from operating use of cash, and management believes current cash and product sales can fund operations for at least 12 months.

Profound Medical Corp. reported strong first quarter 2026 results, with revenue of about $5.3 million, up 104% from the same period in 2025. Capital equipment sales were approximately $2.9 million and recurring non-capital revenue, including one-time use devices and services, was about $2.5 million. Gross margin improved slightly to 72%.

Operating expenses fell 9% to roughly $11.8 million, helping narrow the net loss to about $7.0 million, or $0.19 per share, a 34% improvement year over year. Cash was approximately $50.3 million as of March 31, 2026. Management issued full-year 2026 guidance for $25 million in revenue, implying 56% annual growth, and expects gross margin of at least 70%. The TULSA-PRO installed base reached 80 systems, and Humana became the first U.S. national payor to cover the TULSA Procedure, adding about 8.5 million covered lives.

Profound Medical Corp. announced it will release its first quarter 2026 financial results after market close on Thursday, May 7, 2026, and host a conference call at 4:30 p.m. Eastern Time that day to review the results and discuss business developments.

The company is a commercial-stage medical device business focused on AI-powered, MRI-guided, incision-free therapies. Its flagship TULSA-PRO platform supports MRI-guided prostate therapy, while Sonalleve provides non-surgical, MRI-guided treatments for bone metastases, certain tumors, and gynecologic conditions.

Profound Medical Corp. filed a current report describing its participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference. Management will present a business update on April 22, 2026, at 10:00 a.m. Eastern Time in Toronto, with a live and archived webcast on the company’s website.

The filing includes the related press release as an exhibit and notes that this information is furnished under Regulation FD, meaning it is provided for fair disclosure rather than as part of the company’s formally filed financial statements.

Profound Medical Corp. furnished information that its incision-free, MRI-guided TULSA Procedure™ for prostate disease will be featured in multiple physician presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting in Toronto from April 11-15, 2026.

The TULSA Procedure, performed with the company’s TULSA-PRO® system, uses robotically controlled ultrasound inside the urethra and real-time MRI thermography to ablate prostate tissue at 55-57°C while protecting surrounding structures. Presentations will cover clinical use in prostate cancer and benign prostatic hyperplasia, outcomes data, automated prostate segmentation, and initial perioperative results from the Level 1 post-market CAPTAIN trial.

Profound Medical Corp. filed an 8-K to share a press release celebrating a clinical milestone for its TULSA Procedure™, an MRI-guided, incision-free prostate therapy. Texas Prostate, led by Dr. James Cochran, has now completed its 100th TULSA Procedure in Dallas Medical Center’s MRI suite.

Dr. Cochran notes that switching from focal HIFU to TULSA expanded the range of prostate diseases and sizes he can treat while improving safety. After moving from a private-pay to a Medicare-based model through collaboration with Dallas Medical Center, TULSA volumes at Texas Prostate increased by 500% and continue to grow with referrals from across Texas and nearby states.